RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Modified synthesis of NOP receptor antagonist SB612111
Perrey, D. A., Li, J.-X., & Zhang, Y. (2017). Modified synthesis of NOP receptor antagonist SB612111. Synthesis, 49(6), 1394-1400. https://doi.org/10.1055/s-0036-1588379
SB612111 [(5S, 7S)-7-{[4-(2,6-dichlorophenyl) piperidin-1-yl] methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7] annulen-5-ol] is a potent and selective antagonist of the nociception/orphanin FQ peptide (NOP) receptor. In the process of synthesizing cis-SB612111 to support ongoing animal studies, several key steps of the published syntheses in the patent literature proceeded in low yields in our hands, particularly in the route to the key intermediate 4-(2,6-dichlorophenyl) piperidine, the reduction of 7-[4-(2,6-dichlorophenyl) piperidine-1-carbonyl]-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7] annulen-5-one, the formation of (+/-)-6-methyl-12-oxatricyclo[8.2.1.0(2,7)] trideca-2,4,6-trien-11-one, and the final reductive amination between (+/-)-6-methyl-12-oxatricyclo[ 8.2.1.0(2,7)] trideca-2,4,6-trien-11-ol and 4-(2,6-dichlorophenyl) piperidine in the diastereoselective synthesis. We have thus explored various reaction conditions and successfully improved the yields for the necessary synthetic steps. We herein report our modified synthesis of SB612111 as the cis-diastereomers.
